




LAA and Stroke Prevention



Samuel J. Asirvatham, MD
Professor of Medicine, Professor of Pediatrics
Program Director Cardiac Electrophysiology;
Vice Chair – Innovations Mayo Clinic
Turin, October 26, 2012

Disclosure

I receive royalties for work licensed through Mayo Clinic to a privately held company for contributions related to the use of nerve signal modulation to treat central, autonomic, and peripheral nervous system disorders, including pain. Mayo Clinic receives royalties and owns equity in this company. The company does not currently license or manufacture any drug or device in the medical field.

Co-patent holder for technique to minimize coagulum formation during radiofrequency ablation

Products or techniques related to the above disclosures are not being discussed in this presentation.

Pertains to inventions/startup companies that include Nevro, Aegis, and the Phoenix Corp.

Honoraria/Speakers:

Abiomed

Biotronik

Blackwell Futura

Boston Scientific

Medtronic

Sanofi-aventis

Spectranetics

St. Jude

Consulting:

Sanofi

Stereotaxis

Appendage Ligation and AF Ablation

- Do they work?
- Additional risk
- Additional Benefit
- Approach dependence
- Electrophysiology
- Additional procedures



AF and Stroke

- Risk of stroke 5 times greater in patients with AF than those without¹
- When AF occurs in association with stroke
 - Higher mortality
 - Greater disability
 - Lower discharge rate home
 - 15% risk of stroke recurrence within 1 year, if untreated




¹Wolf PA et al. Stroke 1991;22:983-8.

²Lip GYH, Edwards SJ. Thromb Res 2006;118:321-33.

Stroke Prevention in Non-Rheumatic AF

Aspirin Compared with Placebo




100 50 0 -50 -100
 Aspirin better Aspirin worse

19% reduction

Nondisabling > disabling
 More effective with HTN/DM

Adjusted-Dose Warfarin Compared with Placebo




100 50 0 -50 -100
 Warfarin better Warfarin worse

80% reduction




Annual Rates of Major Hemorrhage During Anticoagulation

Major Bleeding Rate
(%/Year)



Average =
1.2%/yr.



Embolus (blood clot) in cerebral artery blocks blood flow to part of the brain


Location of brain tissue death

Brain

Cerebral arteries within brain


Direction of blood flow

Blood clot breaks off (embolus) from plaque buildup in carotid (neck) artery



Embolus blocking blood flow


Brain tissue death




Warning: Not for diagnostic use

White CJ et al J Am Coll Cardiol 2011;58:101-16.

Since the AF risk factors also cause atherosclerosis, how important is the LAA for stroke in AF?




Stroke: TEE findings for source of Embolism



Association Between AF and Stroke


Mechanism




Implications

- AF **precedes** CVA
- Control of AF may prevent CVA
- LAA closure prevents CVA
- AF burden predicts risk
- **No temporal association between AF and stroke**
- Role of LAA depends on which tissue affected

LAA-Dependent and LAA-Independent Stroke in AF



LAA independent-
arch, carotid,
intracerebral



Aspirin
sensitive


LAA dependent



Warfarin/
anticoagulant
sensitive

Figure 3

A.




Duration: 7 sec

surface

surface

B.



Atrial rate:
270 bpm

atrial

ventricular

ventricular

markers

C.



Atrial rate:
350 bpm


atrial

markers

ventricular


ASSERT: Subclinical AF and Stroke

- Subclinical atrial tachyarrhythmias (SAT) detected in 10.1% at 3 mos
- SATs independently associated with 2.5-fold increased risk of ischemic stroke/SE after adjustment ($p=0.008$)
- Risk independent of other risk factors for stroke and of presence of clinical AF



Temporal Relationship Between AF and Stroke




AT/AF burden (hours/day)



Patient #	CHADS ₂ score	Baseline Antithrombotic therapy
1	2	Therapy
2	3	ASA
3	6	None
4	5	ASA
5	1	OAC
6	4	ASA
7	2	ASA
8	1	OAC/ASA
9	1	OAC
10	3	ASA
11	4	OAC/ASA
12	5	ASA
13	2	None
14	2	None
15	3	ASA
16	3	None
17	3	OAC/ASA
18	4	OAC/ASA
19	2	ASA
20	2	None

Months from CVE

The majority of CVE/SE did not occur proximate to AT/AF episodes





What have we learned from TEE ?


- We do not see often a clot
- When we see a clot it is in the LAA
- LAA has a strange shape prone to clots
- LAA low velocity predisposes to clots






What do we do about it?

LAA Occlusion Devices



**DR Holmes JR. ACC
March 2009






Device Therapy Targeting the Appendage

- Endovascular appendage occlusion
 - WATCHMAN Device
 - Other approaches
- Surgical appendage ligation
- Surgical appendage removal
- Minimally invasive bronchoscopic approaches
- Percutaneous subxiphoid approaches
- Pericardial appendage obliteration

Evidence that Warfarin Prevent stroke via LAA dependent mechanisms



**Intent-to-Treat
All Stroke**



Randomization allocation
(2 device:1 control)

**Key Implication:
Confirms Role
of LAA in CVA**

PROTECT AF Clinical Trial Design

Prospective, randomized study of WATCHMAN LAA Device vs. Long-term Warfarin Therapy

2:1 allocation ratio device to control

800 Patients enrolled from Feb 2005 to Jun 2008

Device Group (463)

Control Group (244)

Roll-in Group (93)

59 Enrolling Centers (U.S. & Europe)

Follow-up Requirements


- TEE follow-up at 45 days, 6 months and 1 year
- Clinical follow-up biannually up to 5 years
- Regular INR monitoring while taking warfarin

Enrollment continues in Continued Access Registry

Intent-to-Treat Primary Safety Results

Randomization allocation (2 device : 1 control)

Cohort	Device			Control			Rel. Risk (95% CI)
	Events (no.)	Total pt-yr	Rate (95% CI)	Events (no.)	Total pt-yr	Rate (95% CI)	
900 pt-yr	48	554.2	8.7 (6.4, 11.3)	13	312.0	4.2 (2.2, 6.7)	2.08 (1.18, 4.13)



244
463

143
261

51
87

11
19

**DR Holmes JR. ACC
March 2009

3001664-1

Intent-to-Treat Primary Safety Results

Randomization allocation (2 device : 1 control)

Cohort	Device			Control			Rel. Risk (95% CI)
	Events (no.)	Total pt-yr	Rate (95% CI)	Events (no.)	Total pt-yr	Rate (95% CI)	
900 pt-yr	48	554.2	8.7 (6.4, 11.3)	13	312.0	4.2 (2.2, 6.7)	2.08 (1.18, 4.13)



244
463

143
261

51
87

11
19

**DR Holmes JR. ACC
March 2009

3001664-1

Basic Procedure Steps

- Access the left atrium via a transseptal approach
- Locate the LAA via fluoroscopy, (TEE) and/or (ICE)
 - Determine size, shape of LAA
 - Select appropriate sized device
- Deliver filter in LAA (distal to LAA ostium)
- Assess device post deployment (confirm: position, size and stability)
- Release the device

31 Oct 03

11:47:20 am

10F10 54Hz

8.5MHz 130mm

Intracardiac

General /V


74dB S1/ 0/0/ 4


Gain= 7dB Δ=1


Store in progress

0:47:33


No R Trig















Ideal Approach


- No need for anticoagulation
- No need to enter the left atrium
- Simple to deploy
- Rapid recovery
- No need for post operative bed rest

Normal Heart

External Topography




R Ant Oblique



L Ant Oblique


Epicardial Approach




- Epicardial approach shown to be feasible for VT ablation in patients with CAD.
 - Complication seen in 4/53 patients in form of RV perforation and tamponade.
- Also effective for other arrhythmias (**VT with & without SHD, WPW, RVOT VT, AT**) especially when endocardial ablation unsuccessful.
 - No complications seen.

Eduardo Sosa, JACC 2000


Schweikert et al. Circulation.
2003;108:1329-1335.




Asirvatham SJ: Innovation Focus: the Patient with Arrhythmia. Journal of Cardiovascular Translational Research 2008; 1:258-272.



e130825-002-01



Electrical Navigation to Move Within the Closed Pericardial Space








Hollow Suture Concept




Closing Hollow Suture Around LAA




No Occlusion




High Jet Flow During Occlusion



**No Flow
Across Ostium
– Complete
Occlusion**




Chronic LAA ligation







Utility of ICE With LAA Closure Device Deployment


- Transseptal access facilitation
- Identification of left atrial appendage ostium
- Exclusion of left atrial or left atrial appendage thrombus
- Identification of unusual left atrial appendage morphology
- Easy discernment from ostium of left-sided pulmonary vein
- Accurate sizing of ostium of the appendage
- Identification of accurate positioning at the mouth of the LAA
- Identification of blood flow around inappropriately-sized device and assessment of stability






Appendage Ligation and AF Ablation

- Do they work?
- Additional risk
- Additional Benefit
- Approach dependence
- Electrophysiology
- Additional procedures




AF and Thrombo-embolism

Atrial fibrillation




- Atria quiver
- Blood clots form in atrial appendage
- Common cause of thromboembolism

PAROXYSMAL




PERSISTANT



Ec300067-001-0

Survival After Stroke

AF Effect




Petty GW et al: *Neurology*
1998; 50:208-216

Atrial Fibrillation is Heterogeneous

||



LAA



Right Atrium

Left Atrium

340



Reporting Results of AF Surgery

Event

Depiction

Freedom from permanent AF

Time-related event depiction
Time zero = 6 months after
date of surgery

Freedom from surgical
failure

Time-related event depiction
Time zero = 6 months after
date of surgery

Prevalence of AF

Prevalence vs time

Time zero = date of surgery

Freedom from stroke

Time-related event depiction
Time zero = date of surgery


Freedom from pacemaker

Time-related event depiction
Time zero = date of surgery





Atrial Fibrillation


Lessons from the OR



THE PULMONARY VEIN POTENTIAL



Asirvatham S: Pulmonary vein-related maneuvers: Part I. Heart Rhythm 2007; 4:538-544






LSPV

LAA

LV

Wide Area Circumferential Ablation: More than Trigger Elimination






Appendage Ligation and AF Ablation

- Do they work?
- Additional risk
- Additional Benefit
- Approach dependence
- Electrophysiology
- Additional procedures




A



CRYOABLATION

- *Stability*
- *↓ Coagulum*
- *↓ Endothelial damage*
- *↓ Collateral injury*





FOCUSED ULTRASOUND

- *? Periosteal*
- *? ↓ Endothelial injury*

D.F.
© MAYO
2006


Ec1249379-001-0







Appendage Ligation and AF Ablation


- Do they work?
- Additional risk
- Additional Benefit
- Approach dependence
- Electrophysiology
- **Additional procedures**





External Cardiac Anatomy

Cardiac Chambers





Superior View

Epicardial Access via RAA



© 2004 Mayo Clinic

One lead to pace LV and defibrillate



Deflection/flexibility could be added to distal screw/tip to facilitate LV placement

Clips for thoracotomy





Figure 1. The atrial exclusion device (AED) consists of 2 stainless



LAA and Stroke Prevention



Samuel J. Asirvatham, MD
Professor of Medicine, Professor of Pediatrics
Program Director Cardiac Electrophysiology;
Vice Chair – Innovations Mayo Clinic
Turin, October 26, 2012